Drugs / Empasiprubart
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07610564 | Jul 2026 → Feb 2028 expected | multifocal motor neuropathy | argenx | Recruiting | No outcome recorded |
| Phase 1 | NCT07612020 | Mar 2026 → Mar 2027 expected | — | argenx | Recruiting | No outcome recorded |
| Phase 1 | NCT04532125 | Aug 2020 → Aug 2022 | — | argenx | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07821762 | Dec 2026 → Jan 2028 expected | Guillain-Barre syndrome | argenx | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07673627 | Jul 2026 → Oct 2027 expected | AChR+ myasthenia gravis, generalized myasthenia gravis | argenx | Recruiting | No outcome recorded |
| Phase 2 | NCT07284420 | Dec 2025 → Mar 2028 expected | AChR+ myasthenia gravis, generalized myasthenia gravis | argenx | Recruiting | No outcome recorded |
| Phase 2 | NCT06284954 | Aug 2024 → Nov 2026 expected | dermatomyositis | argenx | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05907096 | Feb 2024 → Oct 2025 overdue | — | argenx | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05405361 | Jan 2023 → Sep 2029 expected | multifocal motor neuropathy | argenx | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05225675 | Mar 2022 → Jun 2024 | multifocal motor neuropathy | argenx | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07638566 | Sep 2026 → Apr 2028 expected | chronic inflammatory demyelinating polyradiculoneuropathy | argenx | Not yet recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07091630 | Sep 2025 → Oct 2027 expected | chronic inflammatory demyelinating polyradiculoneuropathy, polyneuropathy, inflammatory demyelinating, chronic | argenx | Recruiting | No outcome recorded |
| Phase 3 | NCT06920004 | Aug 2025 → Sep 2027 expected | polyneuropathy, inflammatory demyelinating, chronic | argenx | Recruiting | No outcome recorded |
| Phase 3 | NCT06742190 | Dec 2024 → Sep 2026 overdue | multifocal motor neuropathy | argenx | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-09-29 | argenx | Results argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline argenx.com ↗
Empasiprubart Phase 2 study results in MMN support its potential as a pathway-selective complement therapy |
| 2024-06-25 | argenx | Results argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting argenx.com ↗
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that new data from across the company’s autoimmune pipeline were presented at the 2024 Peripheral Nerve Society (PNS) Annual Meeting in Montréal, Quebec. |
| 2024-01-07 | argenx | Results argenx Highlights 2024 Strategic Priorities argenx.com ↗
Today, argenx reported positive clinical data from the first cohort of the Phase 2 ARDA study of empasiprubart, establishing proof-of-concept in MMN. |
| 2023-06-19 | argenx | Results argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy argenx.com ↗
The IDMC confirmed a favorable safety and tolerability profile of empasiprubart consistent with results from the Phase 1 study and recommended advancing to the second cohort. |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | empasiprubart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06920004 ↗ |
| Known as | ARGX-117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05405361 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314673 ↗ |
| Route | Intravenous | “Subjects receiving ARGX-117 IV” NCT04532125 ↗ |